Today

Agents

Chat

Arena

Discover

More

App

Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026 - ADAG News | Rallies

Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026

ADAG•2026-09-22

Adagene clears NMPA review for ADG138

Adagene announces NMPA clearance of the investigational new drug application for ADG138, a novel HER2xCD3 double-masked bispecific T-cell engager.
Adagene said it will begin a Phase 1 study of ADG138 for advanced solid tumors in Q4 2026.

Related News

Travelers Risk Index puts cyber threats back as top business concern in 2026 survey

TRV•2026-09-22

Amgen says Phase 3 trial shows dazodalibep cuts systemic disease activity in Sjögren’s disease

AMGN•2026-09-22

Interface director Daniel T. Hendrix sells USD 136,200 of common shares

TILE

•

2026-09-22

Laredo Oil Signs First Non-Binding Letter Of Intent For Commercial Deployment Of UGD In Argentina

LRDC•2026-09-22

Rockwell study shows cybersecurity risk ranks among top growth hurdles for over a third of manufacturers

ROK•2026-09-22